Datavant Expands Partnership with Boehringer Ingelheim to Strengthen Real-World Evidence Capabilities
Monday, May 05, 2025
Datavant has extended its partnership with Boehringer Ingelheim to support the pharmaceutical company’s growing focus on real-world evidence (RWE). The collaboration will see Datavant’s data connectivity and privacy-preserving tokenisation technologies applied across 75 additional clinical trials and multiple new molecular entities (NMEs).
The partnership highlights the increasing importance of secure and connected health data in improving understanding of the patient journey. With the use of Datavant Connect, supported by AWS Clean Rooms, Boehringer Ingelheim will be able to explore and analyse third-party data sources without the need to move or share raw data. This approach helps simplify the process of data discovery, linking, and transformation within a secure research environment.
By using Datavant’s technology across a wide range of clinical trials and product launches, Boehringer Ingelheim aims to make better use of real-world data in drug development. This is expected to improve insights into treatment effectiveness, economic outcomes, and long-term patient health.
The integration of tokenisation will be rolled out in phases to align with Boehringer Ingelheim’s existing research systems. The partnership is intended to create a scalable model for future studies and offer a framework for other companies exploring cloud-based RWE strategies.
Source: businesswire.com
